A US biotech has recorded the first continuous read of cortisol taken directly from human skin, using the same aptamer technology that underpins next-generation glucose sensors.

Continuous Cortisol Sensors Edge Closer to the Home Care Market

The continuous glucose monitor did something rare in health technology, it took a number that used to require a needle and a lab, and put it on a phone screen in real time. It reshaped diabetes care in the process, and it did so quietly, through incremental clinical validation rather than launch-day hype. 

Now a US company called Adaptyx Biosciences says it has taken the same approach to a different hormone entirely, and the result is worth the attention of anyone in UK health and social care currently building a remote monitoring strategy, not least the NHS trusts and innovation clusters, such as the £11m wearable programme Greater Manchester recently launched, that are already betting public money on this category maturing.

At the American Diabetes Association’s annual meeting last month, Adaptyx researchers presented what they describe as the first continuous measurement of free cortisol taken from fluid just beneath the skin. Cortisol governs metabolism, sleep, immune response and blood pressure, among other functions, which is precisely why a device that can track it minute by minute has drawn comparisons to the early glucose sensors. Elena Christofides, an endocrinologist who consults for the company, put the scale of the ambition plainly, cortisol, she said, sits at the centre of the body’s biology.

How The Sensor Works And Why It Is Difficult

The patch relies on aptamers, short strands of synthetic DNA engineered to bind to a single target molecule and trigger a small electrical signal when they do. Earlier attempts at this kind of continuous hormone sensing have foundered on the practical demands of real-world use, according to Jason Heikenfeld, who directs the Novel Device Lab at the University of Cincinnati and separately chairs a rival sensor company. He described the field as having spent years wanting to move past glucose without the underlying chemistry being stable enough to allow it. What has changed, on his account, is a convergence of smaller advances in aptamer stability, surface coatings and signal processing, rather than any single breakthrough.

In early testing, the device tracked a hydrocortisone dose against gold-standard blood sampling and also captured the natural overnight rhythm of cortisol, including its disruption after a night of poor sleep and alcohol. No aptamer-based diagnostic device has yet secured regulatory clearance in the United States, and the study itself was a small proof of concept rather than anything approaching a clinical trial. Heikenfeld nonetheless expects continuous cortisol monitors to reach the market before the end of the decade.

The Diabetes Case UK Commissioners Should Note

The clinical case that will matter most to UK integrated care systems sits in diabetes management rather than adrenal disease. A meaningful minority of patients with hard-to-control type 2 diabetes are thought to carry elevated cortisol that raises blood glucose independently of diet or medication adherence, a pattern that current testing rarely catches because it requires a targeted blood draw rather than routine monitoring. A wearable that flags that pattern automatically could, in principle, redirect patients toward the right treatment instead of another round of dose increases, which is exactly the kind of stratification that NHS diabetes technology funding has been trying to buy through other means. For ICBs already managing constrained diabetes prescribing budgets, a sensor that narrows down who actually needs a different treatment pathway is a commissioning question, not just a clinical curiosity.

Adaptyx cofounder and chief science officer Alex Yoshikawa frames the device as a platform rather than a single-purpose sensor, noting that the underlying array already runs multiple channels in parallel and has been adapted to track creatinine, a kidney function marker usually confined to blood tests. That generalisability is the part likely to interest UK remote monitoring providers most, since a platform that can be retuned to different biomarkers fits the direction of travel in community health technology far better than another single-condition device would.

Workforce Stress And The Wellness Market Question

A parallel and rather different market is forming around wellness rather than diagnosis. BioSens8 founder Uroš Kuzmanović wants to sell a cortisol sensor directly to consumers, pointing to the popularity of wearables such as Oura and Whoop, which infer stress from heart rate and temperature rather than measuring a hormone directly. There is an obvious, if untested, read-across into the care workforce itself, where burnout and staff turnover remain persistent problems documented by Skills for Care and others. Whether a stress hormone worn on the wrist would actually change staffing outcomes is a different question from whether it can be measured, and nobody in this field has yet answered it.